Thursday, December 13, 2012

Physicians may actually play a larger role in the selection of products to treat HCV than patients

press release Dec. 13, 2012, 9:00 a.m. EST

Though Hepatitis C Patients Report Having Equal Influence with Their Treating Physicians Regarding the Management and Treatment of Their Disease, Very Few Have Ever Requested Specific Products for Treatment

EXTON, Pa., Dec 13, 2012 (BUSINESS WIRE) -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, overall, hepatitis C (HCV) patients report having equal influence with their doctors regarding the management and treatment of their HCV; however, only three percent of patients report ever requesting a specific brand of HCV treatment, indicating that physicians may actually play a larger role in the selection of products to treat HCV than patients. Furthermore, patients who are currently being treated or who have recently completed treatment for their HCV believe that physicians have more influence over treatment decisions compared to their treatment naive, and prior treatment failure counterparts.

The newest Bio-Trends HCV report entitled PatientTrends(R): Hepatitis C (US) also finds that most surveyed HCV patients do not recall ever having their physician recommend delaying treatment until products in development become available. When physicians do recommend delaying treatment, patients are most commonly told it is because the products in development have improved efficacy and fewer side effects.

"Though overall, just over one-third of the surveyed patients report discussions with their physicians on warehousing, recommendations to delay treatment until products in development become available are significantly more common among patients who have previously failed treatment for their disease than those who are naive," said Bio-Trends Associate Therapeutic Class Director of Gastroenterology, Lynn Price. "Furthermore, significantly more genotype 1 HCV patients--one of the hardest patient groups to treat--report receiving recommendations to delay treatment from their physician than patients with either genotype 2 or genotype 3 HCV."

In terms of future treatment plans, just over one-third of prior treatment failure patients and approximately half of the surveyed treatment naive patients plan to re-treat/treat their HCV within the next year; however, the majority of patients in each group are unaware of what regimen they and their physician intend to initiate.

Less than one-in-five HCV patients have discussed products in development with their doctors at their last appointment. Additionally, overall patient awareness of the HCV pipeline is minimal; less than 10 percent of patients are specifically aware of any of the late stage products in development (Boehringer Ingelheim's faldaprevir, Bristol-Myers Squibb's daclatasvir, Gilead's sofosbuvir, Novartis / Debiopharm's alisporivir or Johnson and Johnson's Tibotec / Medivir's simeprevir).

PatientTrends(R): Hepatitis C (US) is an annual syndicated primary market research report series that provides a comprehensive view of the HCV patient perspective with regard to the treatment and management of their disease. In this report, 253 US HCV patients share their attitudes and perspectives on their disease and treatments, focusing on the patient's path to diagnosis, their perception of their interaction and relationship with their physician, as well as key drivers in the decision to treat now or delay treatment until emerging regimens in development become available. The survey was fielded in late October / early November, and qualitative interview were conducted with a subset of 15 respondents.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or . BioTrends is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE: BioTrends Research Group
        BioTrends Research Group 
        Lynn Price, 610-321-9425 
        Decision Resources Group 
        Christopher Comfort, 781-993-2597

No comments:

Post a Comment